CAPTRUST Financial Advisors’s CorMedix CRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$87.9K Buy
11,420
+224
+2% +$1.8K ﹤0.01% 3166
2026
Q2
$87.9K Buy
11,196
+511
+5% +$4.04K ﹤0.01% 3060
2026
Q1
$72.6K Buy
+10,685
New +$79K ﹤0.01% 2854
2025
Q2
– Sell
-11,013
Closed -$67.8K – 2530
2025
Q1
$67.8K Sell
11,013
-103
-0.9% -$1.07K ﹤0.01% 2266
2024
Q4
$90K Buy
+11,116
New +$111K ﹤0.01% 2211
2022
Q3
– Sell
-1,679
Closed -$7K – 2474
2022
Q2
$7K Buy
1,679
+179
+12% +$665 ﹤0.01% 3912
2022
Q1
$8K Hold
1,500
– – ﹤0.01% 3895
2021
Q4
$7K Sell
1,500
-156
-9% -$774 ﹤0.01% 3895
2021
Q3
$8K Sell
1,656
-785
-32% -$4.57K ﹤0.01% 3723
2021
Q2
$17K Buy
2,441
+941
+63% +$7.49K ﹤0.01% 3210
2021
Q1
$15K Buy
+1,500
New +$15.8K ﹤0.01% 3184

Other funds holding CRMD

CAPTRUST Financial Advisors's CRMD Position: Q3 2026 in Review

CAPTRUST Financial Advisors increased its CorMedix (CRMD) stake by 2% in Q3 2026, buying an estimated $1.8K and bringing the position to 11,420 shares worth $87.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

CAPTRUST Financial Advisors first reported a position in CRMD in Q1 2021 and has held it in 11 quarters since. The position peaked at $90K in Q4 2024. 187 funds tracked by Wall St. Rank hold CRMD as of Q3 2026.

  • CAPTRUST Financial Advisors held 11,420 shares of CorMedix worth $87.9K as of Q3 2026.
  • CAPTRUST Financial Advisors bought 224 CorMedix shares in Q3 2026, an estimated $1.8K.
  • CorMedix made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3166 holding.
  • CAPTRUST Financial Advisors first reported a position in CorMedix in Q1 2021 and has held it in 11 quarters since.
  • CAPTRUST Financial Advisors's CorMedix position peaked at $90K in Q4 2024.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.